Abstract Details

Title Deep Venous Thrombosis in Patients with Stroke and Intracranial Hemorrhage

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P01 - (-)

Poster/Presentation
Number 229

Objective

Background BACKGROUND: Deep venous thrombosis and pulmonary emboli are serious complications in patients admitted with stroke and intracranial hemorrhage. A deeper understanding of the factors that place these patients at risk may help guide therapy.

Design/Methods DESIGN/METHODS: Data on a total of 2613 patients admitted to a large general hospital with stroke, transient ischemic attack (TIA) or intracranial hemorrahge from 1/2008 to 3/2012 were analyzed retrospectively. The data set included 28 variables including length of stay, initial NIH stroke scale, whether the patient had heart failure, was ambulatory by day 2 after admission, had altered mental status, among others. Univariate analyses of effects of each variable on the risk of DVT/PE are carried out followed by linear discriminant analysis. Subsequently a crosstabulation table with the variables significant in the multivariable analysis is computed.

Results RESULTS: In univariable analysis, the risk of DVT/PE was highest in patients with subarachnoid hemorrhage and intracranial hemorrhage and smallest in patients with TIA. Patients with longer length of stay and higher NIH stroke scale as well as patients with altered level of consciousness and heart failure had an increased risk. In the multivariable analysis only whether the patient had altered level of consciousness, heart failure and whether there was an intracranial hemorrhage were statistically significant. Patients with both heart failure and altered level of consciousness had a 7 fold increase in risk for DVT/PE. Whether the patient received prophylaxis with heparin or enoxaparin had no statistically significant effect in any group of patients.

Conclusions CONCLUSIONS: Heart failure and altered level of consciousness are important risk factors for DVT/PE.

Authors/Disclosures
Feliks Koyfman, MD (Westchester Medical Center) PRESENTER	Dr. Koyfman has nothing to disclose.
Mark M. Stecker, MD, FAAN	No disclosure on file
	No disclosure on file
	No disclosure on file
Yuen T. So, MD, PhD, FAAN (Stanford University Dept of Neurology)	No disclosure on file
Thomas A. Berger, MD (Dept. of Neurology, Medical University of Vienna)	Prof. Berger has received personal compensation in the range of $10,000-$49,999 for serving as a speaker at scientific meetings and participant of local and international advisory boards with various companies producing and markerting treatments for multiple sclerosis (Almirall, Biogen, Biologix, Bionorica, Celgene-BMS, Merck, Novartis, Roche, Sanofi-Genzyme, TG Therapeutics, UCB).

��ɫ��

��ɫ��